 | • レポートコード：MRC23Q35775 • 出版社/出版日：QYResearch / 2023年3月 • レポート形態：英文、PDF、85ページ • 納品方法：Eメール（2-3日） • 産業分類：医薬品 |
| Single User | ￥435,000 (USD2,900) | ▷ お問い合わせ |
| Enterprise License | ￥870,000 (USD5,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査レポートは世界の貧血治療薬市場について調査・分析し、世界の貧血治療薬市場概要、市場トレンド、主要企業別競争状況、タイプ別セグメント分析（サプリメント、抗生物質、免疫抑制剤、骨髄刺激剤、コルチコステロイド、遺伝子治療、鉄キレート剤）、用途別セグメント分析（鉄欠乏性貧血、サラセミア、再生不良性貧血、溶血性貧血、鎌状赤血球貧血、悪性貧血）、地域別市場規模、主要企業のプロファイルなどに関する情報を掲載しています。主要企業としては、Pfizer, Inc.、Amgen, Inc.、Hoffmann-La Roche Ltd.、Merck Sharp & Dohme Corp.、Novartis AG、Janssen Pharmaceutical、Bayer AG、AMAG Pharmaceuticals、GlaxoSmithKline plc、Akebia Therapeutics、Vifor Pharma Management, Ltd.、FibroGen, Inc.などが含まれています。世界の貧血治療薬市場は、2022年にXXX米ドル、2029年にはXXX米ドルに達すると予測され、予測期間の年平均成長率はXXX％です。COVID-19とロシア・ウクライナ戦争の影響は、貧血治療薬市場規模を推定する際に考慮しました。本レポートは、貧血治療薬の世界市場を定量的・定性的な分析により包括的に提示し、読者がビジネス/成長戦略を策定し、市場競争状況を把握し、現在の市場における自社のポジションを分析し、貧血治療薬に関するビジネス上の意思決定に役立てることを目的としています。 ・貧血治療薬市場の概要 - 貧血治療薬のタイプ別セグメント - 世界の貧血治療薬市場規模：タイプ別分析（サプリメント、抗生物質、免疫抑制剤、骨髄刺激剤、コルチコステロイド、遺伝子治療、鉄キレート剤） - 貧血治療薬の用途別セグメント - 世界の貧血治療薬市場規模：用途別分析（鉄欠乏性貧血、サラセミア、再生不良性貧血、溶血性貧血、鎌状赤血球貧血、悪性貧血） - 世界の貧血治療薬市場規模予測（2018年-2029年） ・貧血治療薬市場の成長トレンド - 貧血治療薬の地域別市場規模（2018年-2029年） - 貧血治療薬市場ダイナミクス - 貧血治療薬の業界動向 - 貧血治療薬市場の成長ドライバ、課題、阻害要因 ・主要企業別競争状況 - 企業別市場シェア - 世界の主要企業、業界ランキング分析 - 市場への参入、M＆A動向 ・タイプ別セグメント：サプリメント、抗生物質、免疫抑制剤、骨髄刺激剤、コルチコステロイド、遺伝子治療、鉄キレート剤 - 世界の貧血治療薬のタイプ別市場規模（2018年-2023年） - 世界の貧血治療薬のタイプ別市場規模（2024年-2029年） ・用途別セグメント：鉄欠乏性貧血、サラセミア、再生不良性貧血、溶血性貧血、鎌状赤血球貧血、悪性貧血 - 世界の貧血治療薬の用途別市場規模（2018年-2023年） - 世界の貧血治療薬の用途別市場規模（2024年-2029年） ・貧血治療薬の地域別市場規模 - 北米の貧血治療薬市場規模（2018年-2029年） - アメリカの貧血治療薬市場規模（2018年-2029年） - ヨーロッパの貧血治療薬市場規模（2018年-2029年） - アジア太平洋の貧血治療薬市場規模（2018年-2029年） - 中国の貧血治療薬市場規模（2018年-2029年） - 日本の貧血治療薬市場規模（2018年-2029年） - 韓国の貧血治療薬市場規模（2018年-2029年） - インドの貧血治療薬市場規模（2018年-2029年） - オーストラリアの貧血治療薬市場規模（2018年-2029年） - 中南米の貧血治療薬市場規模（2018年-2029年） - 中東・アフリカの貧血治療薬市場規模（2018年-2029年） ・主要企業のプロファイル：企業情報、事業概要、売上、動向 Pfizer, Inc.、Amgen, Inc.、Hoffmann-La Roche Ltd.、Merck Sharp & Dohme Corp.、Novartis AG、Janssen Pharmaceutical、Bayer AG、AMAG Pharmaceuticals、GlaxoSmithKline plc、Akebia Therapeutics、Vifor Pharma Management, Ltd.、FibroGen, Inc. ・アナリストの観点/結論 ・調査方法とデータソース |
Highlights
The global Anemia Therapeutic Drugs market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
North American market for Anemia Therapeutic Drugs is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for Anemia Therapeutic Drugs is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The global market for Anemia Therapeutic Drugs in Iron deficiency anemia is estimated to increase from $ million in 2023 to $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global companies of Anemia Therapeutic Drugs include Pfizer, Inc., Amgen, Inc., Hoffmann-La Roche Ltd., Merck Sharp & Dohme Corp., Novartis AG, Janssen Pharmaceutical, Bayer AG, AMAG Pharmaceuticals and GlaxoSmithKline plc, etc. In 2022, the world’s top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Anemia Therapeutic Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Anemia Therapeutic Drugs.
The Anemia Therapeutic Drugs market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Anemia Therapeutic Drugs market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Anemia Therapeutic Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.
By Company
Pfizer, Inc.
Amgen, Inc.
Hoffmann-La Roche Ltd.
Merck Sharp & Dohme Corp.
Novartis AG
Janssen Pharmaceutical
Bayer AG
AMAG Pharmaceuticals
GlaxoSmithKline plc
Akebia Therapeutics
Vifor Pharma Management, Ltd.
FibroGen, Inc.
Segment by Type
Supplements
Antibiotics
Immunosuppressant
Bone Marrow Stimulants
Corticosteroids
Gene Therapy
Iron Chelating Agents
Segment by Application
Iron deficiency anemia
Thalassemia
Aplastic anemia
Hemolytic anemia
Sickle cell anemia
Pernicious anemia
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Anemia Therapeutic Drugs companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Anemia Therapeutic Drugs Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Supplements
1.2.3 Antibiotics
1.2.4 Immunosuppressant
1.2.5 Bone Marrow Stimulants
1.2.6 Corticosteroids
1.2.7 Gene Therapy
1.2.8 Iron Chelating Agents
1.3 Market by Application
1.3.1 Global Anemia Therapeutic Drugs Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Iron deficiency anemia
1.3.3 Thalassemia
1.3.4 Aplastic anemia
1.3.5 Hemolytic anemia
1.3.6 Sickle cell anemia
1.3.7 Pernicious anemia
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Anemia Therapeutic Drugs Market Perspective (2018-2029)
2.2 Anemia Therapeutic Drugs Growth Trends by Region
2.2.1 Global Anemia Therapeutic Drugs Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Anemia Therapeutic Drugs Historic Market Size by Region (2018-2023)
2.2.3 Anemia Therapeutic Drugs Forecasted Market Size by Region (2024-2029)
2.3 Anemia Therapeutic Drugs Market Dynamics
2.3.1 Anemia Therapeutic Drugs Industry Trends
2.3.2 Anemia Therapeutic Drugs Market Drivers
2.3.3 Anemia Therapeutic Drugs Market Challenges
2.3.4 Anemia Therapeutic Drugs Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Anemia Therapeutic Drugs Players by Revenue
3.1.1 Global Top Anemia Therapeutic Drugs Players by Revenue (2018-2023)
3.1.2 Global Anemia Therapeutic Drugs Revenue Market Share by Players (2018-2023)
3.2 Global Anemia Therapeutic Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Anemia Therapeutic Drugs Revenue
3.4 Global Anemia Therapeutic Drugs Market Concentration Ratio
3.4.1 Global Anemia Therapeutic Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Anemia Therapeutic Drugs Revenue in 2022
3.5 Anemia Therapeutic Drugs Key Players Head office and Area Served
3.6 Key Players Anemia Therapeutic Drugs Product Solution and Service
3.7 Date of Enter into Anemia Therapeutic Drugs Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Anemia Therapeutic Drugs Breakdown Data by Type
4.1 Global Anemia Therapeutic Drugs Historic Market Size by Type (2018-2023)
4.2 Global Anemia Therapeutic Drugs Forecasted Market Size by Type (2024-2029)
5 Anemia Therapeutic Drugs Breakdown Data by Application
5.1 Global Anemia Therapeutic Drugs Historic Market Size by Application (2018-2023)
5.2 Global Anemia Therapeutic Drugs Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Anemia Therapeutic Drugs Market Size (2018-2029)
6.2 North America Anemia Therapeutic Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Anemia Therapeutic Drugs Market Size by Country (2018-2023)
6.4 North America Anemia Therapeutic Drugs Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Anemia Therapeutic Drugs Market Size (2018-2029)
7.2 Europe Anemia Therapeutic Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Anemia Therapeutic Drugs Market Size by Country (2018-2023)
7.4 Europe Anemia Therapeutic Drugs Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Anemia Therapeutic Drugs Market Size (2018-2029)
8.2 Asia-Pacific Anemia Therapeutic Drugs Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Anemia Therapeutic Drugs Market Size by Region (2018-2023)
8.4 Asia-Pacific Anemia Therapeutic Drugs Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Anemia Therapeutic Drugs Market Size (2018-2029)
9.2 Latin America Anemia Therapeutic Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Anemia Therapeutic Drugs Market Size by Country (2018-2023)
9.4 Latin America Anemia Therapeutic Drugs Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Anemia Therapeutic Drugs Market Size (2018-2029)
10.2 Middle East & Africa Anemia Therapeutic Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Anemia Therapeutic Drugs Market Size by Country (2018-2023)
10.4 Middle East & Africa Anemia Therapeutic Drugs Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Pfizer, Inc.
11.1.1 Pfizer, Inc. Company Detail
11.1.2 Pfizer, Inc. Business Overview
11.1.3 Pfizer, Inc. Anemia Therapeutic Drugs Introduction
11.1.4 Pfizer, Inc. Revenue in Anemia Therapeutic Drugs Business (2018-2023)
11.1.5 Pfizer, Inc. Recent Development
11.2 Amgen, Inc.
11.2.1 Amgen, Inc. Company Detail
11.2.2 Amgen, Inc. Business Overview
11.2.3 Amgen, Inc. Anemia Therapeutic Drugs Introduction
11.2.4 Amgen, Inc. Revenue in Anemia Therapeutic Drugs Business (2018-2023)
11.2.5 Amgen, Inc. Recent Development
11.3 Hoffmann-La Roche Ltd.
11.3.1 Hoffmann-La Roche Ltd. Company Detail
11.3.2 Hoffmann-La Roche Ltd. Business Overview
11.3.3 Hoffmann-La Roche Ltd. Anemia Therapeutic Drugs Introduction
11.3.4 Hoffmann-La Roche Ltd. Revenue in Anemia Therapeutic Drugs Business (2018-2023)
11.3.5 Hoffmann-La Roche Ltd. Recent Development
11.4 Merck Sharp & Dohme Corp.
11.4.1 Merck Sharp & Dohme Corp. Company Detail
11.4.2 Merck Sharp & Dohme Corp. Business Overview
11.4.3 Merck Sharp & Dohme Corp. Anemia Therapeutic Drugs Introduction
11.4.4 Merck Sharp & Dohme Corp. Revenue in Anemia Therapeutic Drugs Business (2018-2023)
11.4.5 Merck Sharp & Dohme Corp. Recent Development
11.5 Novartis AG
11.5.1 Novartis AG Company Detail
11.5.2 Novartis AG Business Overview
11.5.3 Novartis AG Anemia Therapeutic Drugs Introduction
11.5.4 Novartis AG Revenue in Anemia Therapeutic Drugs Business (2018-2023)
11.5.5 Novartis AG Recent Development
11.6 Janssen Pharmaceutical
11.6.1 Janssen Pharmaceutical Company Detail
11.6.2 Janssen Pharmaceutical Business Overview
11.6.3 Janssen Pharmaceutical Anemia Therapeutic Drugs Introduction
11.6.4 Janssen Pharmaceutical Revenue in Anemia Therapeutic Drugs Business (2018-2023)
11.6.5 Janssen Pharmaceutical Recent Development
11.7 Bayer AG
11.7.1 Bayer AG Company Detail
11.7.2 Bayer AG Business Overview
11.7.3 Bayer AG Anemia Therapeutic Drugs Introduction
11.7.4 Bayer AG Revenue in Anemia Therapeutic Drugs Business (2018-2023)
11.7.5 Bayer AG Recent Development
11.8 AMAG Pharmaceuticals
11.8.1 AMAG Pharmaceuticals Company Detail
11.8.2 AMAG Pharmaceuticals Business Overview
11.8.3 AMAG Pharmaceuticals Anemia Therapeutic Drugs Introduction
11.8.4 AMAG Pharmaceuticals Revenue in Anemia Therapeutic Drugs Business (2018-2023)
11.8.5 AMAG Pharmaceuticals Recent Development
11.9 GlaxoSmithKline plc
11.9.1 GlaxoSmithKline plc Company Detail
11.9.2 GlaxoSmithKline plc Business Overview
11.9.3 GlaxoSmithKline plc Anemia Therapeutic Drugs Introduction
11.9.4 GlaxoSmithKline plc Revenue in Anemia Therapeutic Drugs Business (2018-2023)
11.9.5 GlaxoSmithKline plc Recent Development
11.10 Akebia Therapeutics
11.10.1 Akebia Therapeutics Company Detail
11.10.2 Akebia Therapeutics Business Overview
11.10.3 Akebia Therapeutics Anemia Therapeutic Drugs Introduction
11.10.4 Akebia Therapeutics Revenue in Anemia Therapeutic Drugs Business (2018-2023)
11.10.5 Akebia Therapeutics Recent Development
11.11 Vifor Pharma Management, Ltd.
11.11.1 Vifor Pharma Management, Ltd. Company Detail
11.11.2 Vifor Pharma Management, Ltd. Business Overview
11.11.3 Vifor Pharma Management, Ltd. Anemia Therapeutic Drugs Introduction
11.11.4 Vifor Pharma Management, Ltd. Revenue in Anemia Therapeutic Drugs Business (2018-2023)
11.11.5 Vifor Pharma Management, Ltd. Recent Development
11.12 FibroGen, Inc.
11.12.1 FibroGen, Inc. Company Detail
11.12.2 FibroGen, Inc. Business Overview
11.12.3 FibroGen, Inc. Anemia Therapeutic Drugs Introduction
11.12.4 FibroGen, Inc. Revenue in Anemia Therapeutic Drugs Business (2018-2023)
11.12.5 FibroGen, Inc. Recent Development
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details